Finland’s CurifyLabs raises €12 million to expand 3D printing-based medicine compounding
Helsinki-based HealthTech company CurifyLabs has closed a €12 million Series A round to expand U.S. operations, strengthen supply chain infrastructure, and accelerate product innovation.
CurifyLabs, a HealthTech company based in Helsinki, Finland, announced today the closing of a €12 million ($14 million) Series A funding round. The company specializes in transforming the production of personalized medicines through 3D printing technology.
The round was co-led by Sandwater and HealthCap, with participation from Tesi (Finnish Industry Investment Ltd.). The funds will be used to expand operations in the United States, strengthen supply chain infrastructure, enhance customer support, and accelerate product innovation.
CurifyLabs develops solutions that enable pharmacies and hospitals to produce customized drug forms using 3D printing. This technology is particularly beneficial for pediatric, geriatric, and other patient groups requiring non-standard dosages or drug formulations.
